News

Preliminary data shows an anthracycline/taxane-based chemotherapy regimen (TaxAC) could be superior to docetaxal plus cyclophosphamide in patients with breast cancer.

Screening for microsatellite instability in patients with colorectal cancer tumors is a significant step in determining which patients will benefit from immunotherapy, specifically pembrolizumab.

Multigene panel testing may uncover new risks in breast cancer and ovarian cancer.

Many patients with metastatic colorectal cancer (CRC) will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.

Therapeutic options have been severely limited for patients with locally advanced or unresectable basal cell carcinoma.

Hendrik-Tobias Arkenau, MD, PhD, discusses the phase I JAVELIN trial as well as the future of treatments and immunotherapies in the treatment paradigm of gastrointestinal cancers.

A phase Ib trial shows strong potential for the use of utomilumab in combination with pembrolizumab (Keytruda) for patients with advanced solid tumors, according to Anthony Tolcher, MD.

TNFSF11, also known as RANKL, shows potential as a genetic pathway in the prevention of breast cancer for women carrying BRCA1 mutations. Early study findings, published in Nature Medicine, show that a drug currently used in the treatment of osteoporosis, denosumab (Xgeva)-an inhibitor of RANKL-could also be used for the prevention and delay of tumor growth for BRCA1-mutation carriers.

The combination of nivolumab (Opdivo) and ipilimumab showed efficacy in a recent study looking at patients with colorectal cancer (CRC), according to Michael Overman, MD.

Colorectal cancer (CRC) patients that express amplified HER2 genes may be resistant to standard-of care therapy, says Kanwal Raghav, MD.

Current progress on targeted and immunotherapy agents for the treatment of sarcomas from the 2016 ASCO Annual Meeting were discussed with Jonathan C. Trent, MD, PhD.

The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) continues to show promise, with recent data demonstrating a 26% improvement in overall survival (OS) with the 2 drugs compared with ipilimumab alone for patients with advanced melanoma.

The National Institute for Health and Care Excellence (NICE) has approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with metastatic melanoma, which allows the combination to be used within the National Health Service (NHS).

Choosing between immunotherapy and targeted therapy in the frontline setting for patients with BRAF-mutated melanoma does not have to be a guessing game, according to Keith T. Flaherty, MD.

The United States Preventative Services Task Force (USPSTF) has updated its 2008 recommendation for colorectal cancer (CRC) screening to include 7 CRC screening tests for average-risk, asymptomatic adults between the ages of 50 and 75 to reduce the risk of CRC mortality.

Although nivolumab (Opdivo) and ipilimumab (Yervoy) are approved in combination for the first-line treatment of patients with metastatic melanoma, regardless of BRAF mutation status, the checkpoint blockade has not automatically become the standard of care in this setting.

While the ALSYMPCA trial led to the FDA approval of radium-223 dichloride (Xofigo), the phase III study left several questions to be answered regarding its use in metastatic castration-resistant prostate cancer (mCRPC), says Luke Nordquist, MD.

Patients with nonfunctioning neuroendocrine tumors of gastrointestinal or lung origin continued to live longer when treated with the mammalian target of rapamycin (mTOR) inhibitor everolimus than with placebo, ongoing follow-up in a randomized trial showed.

Dual autologous stem-cell transplant (ASCT) led to a 13% absolute increase in 3-year event-free survival (EFS) for children with high-risk neuroblastoma as compared with a single transplant, a large randomized trial showed.

Researchers are hoping the results of a latestage efficacy and safety study of apalutamide (ARN-509) in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival, according to global principal investigator, Howard M. Sandler, MD.

Patients with anaplastic glioma who did not have a co-deleted 1p/19q chromosome, may have a new standard of care, according to Martin J. van den Bent, MD.

Patients with high-risk, low-grade glioma may soon benefit from radiation plus procarbazine, CCNU, and vincristine (PCV), according to Erica Bell, MD.

The combinations of nivolumab (Opdivo) plus ipilimumab (Yervoy) and pembrolizumab (Keytruda) plus bevacizumab (Avastin ), both show promising efficacy in recent trials, possibly paving the way toward a new era of treatment for patients with glioblastoma.

The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin demonstrated significantly improved progression-free survival (PFS) and complete remission (CR) rates compared with chemotherapy for patients with relapsed or refractory acute lymphoblastic leukemia (ALL).

Final 5-year efficacy and safety data from the phase III COMFORT-I trial confirm previous findings that ruxolitinib (Jakafi) confers a significant benefit in patients with intermediate-2 and high-risk myelofibrosis. The JAK-2 inhibitor resulted in durable reductions in splenomegaly and improved overall survival, with patients experiencing no new or unexpected adverse events as a result of the long-term treatment.

Ibrutinib (Imbruvica) continued to demonstrate impressive antitumor activity in a pooled analysis of 243 patients with deletion 17p chronic lymphocytic leukemia.

Daratumumab (Darzalex), when added to the standard two-drug regimen of bortezomib and dexamethasone, reduced the risk of progression or death by 61% compared with the standard regimen alone for patients with recurrent or refractory multiple myeloma.

A regimen consisting of carfilzomib (Kyprolis), pomalidomide (Pomalyst), and dexamethasone (KPd) merits further investigation for the treatment of patients with multiple myeloma whose disease progresses while on lenalidomide (Revlimid) in the earlier stages of disease.

The anti-CD38 monoclonal antibody isatuximab (SAR650984) showed promising signs of activity as a single-agent for patients with heavily pretreated relapsed/refractory multiple myeloma, according to updated findings from a phase II study presented at the 2016 ASCO Annual Meeting.

Gastric cancers with high-level clonal FGFR2 gene amplification responded to AZD4547, a selective FGFR inhibitor, in a phase II open label trial of previously treated, advanced FGFR amplified cancer. Yet tumors with multiple FGFR1 genes, low level or subclonal amplification of FGFR2 did not respond similarly to the drug.